ArticleNature genetics2024
Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia.
Abstract read
In one paragraph
Article in Nature genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Putting the I in AML: Artificial Intelligence and Machine Learning in Acute Myeloid Leukemia.Cells · 2026Review
- Article
- Article
- Clinical and sociodemographic predictors of intensive care unit admission following chemotherapy in acute myeloid leukemia.Haematologica · 2026Article
- Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex.American journal of hematology · 2026Observational
- Understanding the impact of social determinants of health in hematology: a scoping review of trends across journals and over time.Blood advances · 2026Article
- Outcome of Acute Myeloid Leukemia Treatment and Isocitrate Dehydrogenase (IDH) Mutations: A Systematic Review and Meta-Analysis Study.International journal of hematology-oncology and stem cell research · 2026Review
- Impact of demographic factors on clinical outcomes of patients with acute myeloid leukemia.Haematologica · 2026Article
- Article
- AML Disparities Across Racial Ancestry Groups: A Spotlight on the NPM1 Mutations.International journal of molecular sciences · 2026Review
- Health Disparities in Acute Myeloid Leukemia Patients Undergoing Treatment with Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2.Blood and lymphatic cancer : targets and therapy · 2026Article
- scDNA: Single Cell DNA analysis software toolkit for subclonality discovery and assessment.bioRxiv : the preprint server for biology · 2025Article
- Development of a Dynamic Counterfactual Risk Stratification Strategy for Newly Diagnosed Patients With AML Treated With Venetoclax and Azacitidine.JCO clinical cancer informatics · 2025Article
- Prognostic and Therapeutic Implications ofbioRxiv : the preprint server for biology · 2025Article
- Review
- Leukemia mutated proteins PHF6 and PHIP form a chromatin complex that represses acute myeloid leukemia stemness.Genes & development · 2025Article
- A new link in the leukemia genetic puzzle.Genes & development · 2025Review
- Identification and validation of immune-associated gene signatures for prognostic prediction in acute myeloid leukemia.Medicine · 2025Article
- Classification of acute myeloid leukemia based on multi-omics and prognosis prediction value.Molecular oncology · 2025Article
- Addressing Health Disparities in Hematologic Malignancies: from Genes to Outreach.Blood cancer discovery · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
64 authors.
Andrew Stiff *The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Maarten Fornerod *Department of Cell Biology, Erasmus Medical Center, Rotterdam, the Netherlands.ORCID http://orcid.org/0000-0002-6166-3030
Bailee N Kain *Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.ORCID http://orcid.org/0000-0002-8407-9937
Deedra NicoletThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.ORCID http://orcid.org/0000-0001-7796-0251
Benjamin J KellyThe Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.ORCID http://orcid.org/0000-0002-7796-3994
Katherine E MillerThe Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.
Krzysztof MrózekThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.ORCID http://orcid.org/0000-0002-1408-5063
Isaiah BoatengThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Audrey BollasThe Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.
Elizabeth A R GarfinkleThe Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.
Omolegho MomohDepartment of Internal Medicine, Montefiore Health System/Albert Einstein College of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0003-3210-5272
Foluke A FasolaDepartment of Hematology, Faculty of Basic Medical Science, University of Ibadan, University College Hospital, Ibadan, Nigeria.
Hannah O OlawumiDepartment of Haematology, University of Ilorin, Ilorin, Nigeria.
Nuria Mencia-TrinchantDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Jean F KloppersSchool of Pathology, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa.ORCID http://orcid.org/0000-0002-8148-1242
Anne-Cecilia van MarleSchool of Pathology, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa.ORCID http://orcid.org/0000-0002-6569-4061
Eileen HuThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Saranga WijeratneThe Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.
Gregory WheelerThe Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.ORCID http://orcid.org/0000-0002-3291-6537
Christopher J WalkerThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Jill BussThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Adrienne HeyrosaThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Helee DesaiThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Andrea LagansonThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Ethan HampThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Yazan Abu-ShihabThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Hasan AbazaThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Parker KronenThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Sidharth SenDivison of Biomedical Informatics, Cincinnati Children's Hospital, Cincinnati, OH, USA.
Megan E JohnstoneDepartment of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA.
Kate QuinnDepartment of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA.ORCID http://orcid.org/0009-0004-2766-3303
Ben WronowskiDepartment of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA.
Erin HertleinDepartment of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA.
Linde A MilesCancer and Blood Diseases Institute, Cincinnati Children's Hospital, Cincinnati, OH, USA.ORCID http://orcid.org/0000-0003-3578-2842
Alice S MimsThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.ORCID http://orcid.org/0000-0002-8971-2199
Christopher C OakesThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.ORCID http://orcid.org/0000-0001-8000-9694
James S BlachlyThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.ORCID http://orcid.org/0000-0002-4275-5562
Karilyn T LarkinThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.ORCID http://orcid.org/0000-0002-1898-9836
Bethany Mundy-BosseThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Andrew J CarrollDepartment of Genetics, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID http://orcid.org/0000-0001-9844-730X
Bayard L PowellAtrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USA.
Jonathan E KolitzMonter Cancer Center, Hofstra Northwell School of Medicine, Lake Success, NY, USA.
Richard M StoneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7526-2633
Cassandra DuarteUniversity of Colorado, Anschutz Medical Campus, College of Medicine, Denver, CO, USA.
Diana AbbottUniversity of Colorado, Anschutz Medical Campus, College of Medicine, Denver, CO, USA.
Maria L AmayaUniversity of Colorado, Anschutz Medical Campus, College of Medicine, Denver, CO, USA.
Craig T JordanUniversity of Colorado, Anschutz Medical Campus, College of Medicine, Denver, CO, USA.ORCID http://orcid.org/0000-0003-0869-3465
Geoffrey L UyWashington University School of Medicine, Saint Louis, MO, USA.
Wendy StockUniversity of Chicago, College of Medicine, Chicago, IL, USA.
Kellie J ArcherDivision of Biostatistics, College of Public Health, The Ohio State University, Columbus, OH, USA.ORCID http://orcid.org/0000-0003-1555-5781
Electra D PaskettThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Monica L GuzmanDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Ross L LevineMemorial Sloan-Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-7884-1905
Kamal MenghrajaniMemorial Sloan-Kettering Cancer Center, New York, NY, USA.
Debyani ChakravartyMemorial Sloan-Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-8629-5732
Michael F BergerMemorial Sloan-Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-3882-5000
Daniel BottomlyKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Shannon K McWeeneyKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.ORCID http://orcid.org/0000-0001-8333-6607
Jeffrey W TynerKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.ORCID http://orcid.org/0000-0002-2133-0960
John C ByrdDepartment of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA.
Nathan SalomonisDivision of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.ORCID http://orcid.org/0000-0001-9689-2469
H Leighton GrimesDivision of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.ORCID http://orcid.org/0000-0001-8162-6758
Elaine R MardisThe Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA. Elaine.Mardis@nationwidechildrens.org.ORCID http://orcid.org/0000-0002-5892-1553
Ann-Kathrin EisfeldThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. Ann-Kathrin.Eisfeld@osumc.edu.ORCID http://orcid.org/0000-0001-6442-1419
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MMember Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3MSWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1MTranslational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3MStatistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0MWake Forest NCORP Research BaseUG1CA189824 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Emily Van Meter Dressler, GLENN J LESSER · 2014 to 2026
$57.9MTHE ALLIANCE NCTN BIOREPOSITORY AND BIOSPECIMEN RESOURCEU24CA196171 · NCI · WASHINGTON UNIVERSITY · PI Mine Cicek, Wendy Frankel · 2015 to 2026
$35.0MNorthwell Health NCORPUG1CA189850 · NCI · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI VINCENT P VINCIGUERRA · 2014 to 2026
$13.3MSynergistic role of signaling and epigenetics in leukemic transformationR35CA197594 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Ross L Levine · 2017 to 2026
$11.4MSPORE Leukemia Tissue BankP50CA140158 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D · 2009 to 2013
$11.2MNetwork Lead Academic Participating Site: Memorial Sloan Kettering Cancer CenterUG1CA233290 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CAROL AGHAJANIAN, Darren Feldman · 2019 to 2026
$10.2MOSU as a Network Lead Academic Participating Site for the NCI NCTNUG1CA233331 · NCI · OHIO STATE UNIVERSITY · PI John L. Hays, Dwight H. Owen · 2019 to 2026
$8.9MConquer Cancer Foundation (Conquer Cancer Foundation of the American Society of Clinical Oncology) 2023YIA-5335030875NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016058NCI NIH HHS P50 CA140158NCI NIH HHS R01 CA262496NCI NIH HHS R01 CA283574NCI NIH HHS R01 CA284595NCI NIH HHS R35 CA197594NCI NIH HHS R35 CA197734NCI NIH HHS R50 CA275927NCI NIH HHS T32 CA117846NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180867NCI NIH HHS U10 CA180882NCI NIH HHS U10 CA180888NCI NIH HHS U24 CA196171NCI NIH HHS UG1 CA189824NCI NIH HHS UG1 CA189850NCI NIH HHS UG1 CA233180NCI NIH HHS UG1 CA233290NCI NIH HHS UG1 CA233327NCI NIH HHS UG1 CA233331NCI NIH HHS UG1 CA233338NLM NIH HHS R01 LM013879U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01 CA283574-01U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01 CA284595-01
Abstract
Genomic profiles and prognostic biomarkers in patients with acute myeloid leukemia (AML) from ancestry-diverse populations are underexplored. We analyzed the exomes and transcriptomes of 100 patients with AML with genomically confirmed African ancestry (Black; Alliance) and compared their somatic mutation frequencies with those of 323 self-reported white patients with AML, 55% of whom had genomically confirmed European ancestry (white; BeatAML). Here we find that 73% of 162 gene mutations recurrent in Black patients, including a hitherto unreported PHIP alteration detected in 7% of patients, were found in one white patient or not detected. Black patients with myelodysplasia-related AML were younger than white patients suggesting intrinsic and/or extrinsic dysplasia-causing stressors. On multivariable analyses of Black patients, NPM1 and NRAS mutations were associated with inferior disease-free and IDH1 and IDH2 mutations with reduced overall survival. Inflammatory profiles, cell type distributions and transcriptional profiles differed between Black and white patients with NPM1 mutations. Incorporation of ancestry-specific risk markers into the 2022 European LeukemiaNet genetic risk stratification changed risk group assignment for one-third of Black patients and improved their outcome prediction.
Indexed as
Black or African AmericanLeukemia, Myeloid, AcuteMutationNucleophosminAdultAgedBiomarkers, TumorFemaleGene Expression ProfilingGTP PhosphohydrolasesHumansIsocitrate DehydrogenaseMaleMembrane ProteinsMiddle AgedNuclear ProteinsBiomarkers, TumorGTP PhosphohydrolasesIDH1 protein, humanIDH2 protein, humanIsocitrate DehydrogenaseMembrane ProteinsNPM1 protein, humanNRAS protein, humanNuclear ProteinsNucleophosmin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.